权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Use of a CB2 Ligand to prevent HIV-1 Infection and Transmission

使用 CB2 配体预防 HIV-1 感染和传播

基本信息

批准号：
8681359
负责人：
Seyoum Ayehunie
金额：
$ 22.2万
依托单位：
MATTEK CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-06-17 至 2015-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8681359
关键词：
Adherent Culture Adjuvant Agonist Animal Model Anti-Inflammatory Agents Anti-Retroviral Agents Anti-inflammatory Antiviral Agents Applications Grants Biological Assay Blood Brain CD4 Positive T Lymphocytes CNR1 gene CNR2 gene Cannabinoids Cell Adhesion Molecules Cell Count Cell Maturation Cells Chronic Clinical Trials Dendritic Cells Disease Progression Edetic Acid Electrical Resistance Endothelial Cells Epithelial Epithelial Cells Epithelium Exposure to Foundations Gene Expression Genome Goals HIV HIV Envelope Protein gp120 HIV Infections HIV tat Protein HIV-1 Human Immune system Immunologics In Vitro Infection Inflammation Investigation Langerhans cell Lead Leukocytes Ligands Lymphocyte Macaca Male Circumcision Measures Mediator of activation protein Messenger RNA Modeling Morbidity - disease rate Natural Immunity Oral Pattern Peripheral Permeability Pharmaceutical Preparations Production Property Proteins Recovery Regulation Research Resistance Risk SIV Sexual Transmission Stratification Structure System T-Cell Activation TNF gene Testing Tetrahydrocannabinol Therapeutic Thick Tight Junctions Tissues Topical application Vagina Viral Load result Work attenuation cannabinoid receptor cell motility chemokine condoms cytokine interest intestinal epithelium mRNA Expression macrophage microbicide migration monocyte mortality pre-clinical preclinical study prevent prophylactic public health relevance receptor expression reproductive hormone trafficking transmission process

项目摘要

DESCRIPTION: The goal of this R21 grant proposal is to test the feasibility of using cannabinoid receptor (CB) agonists as microbicides to prevent HIV infection and transmission. These non-psychoactive derivatives of tetrahydrocannabinol (THC) have a broad range of anti-inflammatory properties and increase the stratification of vaginal tissue in animal models. The compounds to be tested are agonists of CB2, which are found in the immune system and also present in other peripheral tissues, including vaginal tissue. During the R21 project, the effect o these agonists on the: 1) vaginal tissue thickness, tight junctions, gene expression, and barrier function, 2) expression of factors involved in innate immunity, 3) expression of CB2 in epithelial tissues and HIV host cells, 4) migration of HIV infected cells within vaginal tissue, and 5) capture and transfer HIV to CD4+ T cells will be investigated. Successful completion of the R21 work is anticipated to lead to advancement of one of the CB agonists into preclinical/clinical trials for use as a prophylactic HIV treatment or as an HIV microbicide adjuvant.

产品说明：这项R21赠款提案的目标是测试使用大麻素受体（CB）激动剂作为杀微生物剂预防艾滋病毒感染和传播的可行性。这些四氢大麻酚（THC）的非精神活性衍生物具有广泛的抗炎特性，并增加动物模型中阴道组织的分层。待测试的化合物是CB 2的激动剂，CB 2存在于免疫系统中，也存在于其他外周组织中，包括阴道组织。在R21项目期间，将研究这些激动剂对以下方面的影响：1）阴道组织厚度、紧密连接、基因表达和屏障功能，2）先天免疫相关因子的表达，3）上皮组织和HIV宿主细胞中CB 2的表达，4）HIV感染细胞在阴道组织内的迁移，以及5）将HIV捕获并转移至CD 4 + T细胞。R21工作的成功完成预计将导致CB激动剂之一进入临床前/临床试验，用作预防性HIV治疗或HIV杀微生物剂佐剂。